CDT1656

**CDT1656** is an investigational small-molecule cocrystal combination developed by CDT Equity, formerly Conduit Pharmaceuticals, for autoimmune disorders. It combines the glucokinase activator AZD1656 with a second known compound reported to have immune-modulating activity across autoimmune conditions; the identity and molecular target of that second component have not been publicly disclosed. The program is being positioned for lupus and ANCA-associated vasculitis, with the cocrystal approach intended to create a distinct composition-of-matter asset and potentially improve pharmaceutical properties while retaining AZD1656-related glucokinase biology. ([s3.amazonaws.com](https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl139902.pdf))